GGrantIndex
Sort

172,184 grants matching inflammation

MicroRNA in Functional Regulation of Endothelial Cells in Response to Flow

$784,276
Shu Chien · University Of California, San Diego · R01 · FY2012 · HL

Modulation of innate and adaptive immunity of filoviruses in macaques

$784,263
Thomas William Geisbert · Icahn School Of Medicine At Mount Sinai · U19 · FY2015 · AI

Virulence in Enteroaggregative Escherichia coli

$784,254
James P. Nataro · University Of Virginia · R01 · FY2011 · AI

ECPR After Prolonged Cardiac Arrest: Targeting Mechanisms of the No-Reflow

$784,250
Robert W Neumar · University Of Michigan At Ann Arbor · R01 · FY2018 · HL

Role of TNF receptor 2 on Pulmonary Group 2 Innate Lymphoid Cells

$784,241
Omid Akbari · University Of Southern California · R01 · FY2022 · HL

Role of TNF receptor 2 on Pulmonary Group 2 Innate Lymphoid Cells

$784,241
Omid Akbari · University Of Southern California · R01 · FY2023 · HL

Macrophages in Myocardial Infarction

$784,206
Nikolaos G Frangogiannis · Albert Einstein College Of Medicine · R01 · FY2025 · HL

Innate Immune Clearance of Host-Adapted Pulmonary Pathogens

$784,138
Alice S Prince · Columbia University Health Sciences · R35 · FY2019 · HL

Impact of microbiota on AIDS-Kaposi’s sarcoma development and therapy

$784,127
Shou-Jiang Gao · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · CA

Mechanisms and interventions addressing accelerated cardiovascular disease risk in women with endometriosis

$784,116
Lacy M. Alexander · Pennsylvania State University, The · R01 · FY2022 · HL

Phase 2 placebo-controlled randomized trial of LACTIN-V (Lactobacillus crispatus CTV-05) among women at high risk of HIV acquisition in Durban, South Africa

$784,076
Craig R Cohen · University Of California, San Francisco · R01 · FY2019 · HD

Role of Th17 in Severe and Recurrent C. difficile Infection

$784,076
William A Petri · University Of Virginia · R01 · FY2022 · AI

First-in-Human evaluation of an astrocytic glutamate transporter (EAAT2) PET tracer in healthy and Alzheimer's diseased brain

$784,058
David M Wilson · University Of California, San Francisco · R01 · FY2022 · AG

Developing novel therapies to improve blood stem cell transplantation outcomes

$783,992
Ramiro Garzon · Ohio State University · R01 · FY2022 · HL

Local B-1 Regulation of Atherosclerosis

$783,960
Coleen A McNamara · University Of Virginia · R01 · FY2017 · HL

NINDS CREATE DISCOVERY: Development of dendrimer-N-acetylcysteine for the treatment of neonatal brain injury

$783,954
Kannan Rangaramanujam · Johns Hopkins University · U01 · FY2018 · NS

Understanding and Mitigating Vascular Side-Effects Associated with Anti-Amyloid Immunotherapy

$783,917
Cynthia A Lemere · Brigham And Women'S Hospital · R01 · FY2025 · NS

Mechanisms of atherosclerotic cardiovascular complications

$783,846
Chiara Giannarelli · New York University School Of Medicine · R01 · FY2025 · HL

Mechanisms of atherosclerotic cardiovascular complications in COVID19

$783,846
Chiara Giannarelli · New York University School Of Medicine · R01 · FY2023 · HL

Beta3 Integrins - Translation of Molecular Structure to Improved Therapeutics

$783,775
Barry Coller · Rockefeller University · R01 · FY2020 · HL

ADMINISTRATIVE CORE, CENTER DIRECTOR, ENRICHMENT PROGRAM

$783,750
Ramnik J Xavier · Massachusetts General Hospital · P30 · FY2011 · DK

Immune based interventions for HIV eradication

$783,714
Mirko Paiardini · Emory University · R01 · FY2019 · AI

The role of N6-methyladenosine modified RNA in Alzheimer's disease

$783,699
Benjamin L Wolozin · Boston University Medical Campus · R01 · FY2024 · AG

A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis

$783,698
Abigail Pulsipher · Glycomira, Llc · R44 · FY2020 · AI

METABOLIC ALDEHYDES AS IMMUNE EFFECTORS AGAINST TUBERCULOSIS

$783,685
Katerina Heran Darwin · New York University School Of Medicine · R01 · FY2024 · AI